PARACETAMOL IV MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Name: Paracetamol IV Market News
Creator: Coherent Market Insights
License: https://www.coherentmarketinsights.com/privacy-policy
Keywords: Paracetamol IV Market Size, Paracetamol IV Market Share, Paracetamol IV Market Trends, Paracetamol IV Market Growth, Paracetamol IV Market Analysis, Paracetamol IV Market Forecast, Paracetamol IV Market Report, Paracetamol IV Industry Report

Paracetamol IV Market, By Type (Single Dose and Multi-Dose), By Application (Pain Management and Fever Reduction), By End User (Hospitals, Clinics, Homecare Settings, and Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Dec 2024
Code : CMI7565
Pages :151
Formats :
Excel and PDF
Industry : Pharmaceutical

Key Developments

In July 2024, Hyloris Pharmaceuticals partnered with Halex Istar, both pharmaceutical companies, to distribute Maxigesic IV in Brazil, expanding access to non-opioid pain relief. This partnership supports Hyloris's goal of addressing unmet medical needs while anticipating revenue growth through royalties and milestone payments.
In May 2024, as per a National Institute of Health-supported clinical trial, intravenous acetaminophen reduced the risk of organ injury and acute respiratory distress syndrome in sepsis patients, particularly those at higher risk. While it did not improve overall mortality, it helped the most critically ill patients by reducing the need for assisted ventilation. The study suggests that testing for high levels of cell-free hemoglobin could help identify patients who would benefit most from acetaminophen therapy.
In January 2023, Hyloris Pharmaceuticals partnered with Salus Pharmaceuticals for exclusive licensing and distribution of Maxigesic IV in nine European countries. This non-opioid pain treatment combines paracetamol and ibuprofen, with launches in 2023, supporting Hyloris's strategy to expand non-opioid pain management options.